CyberKnife (system of radiation therapy)

2020: Announcement of CyberKnife S7

In the middle of June, 2020 Accuray submitted the CyberKnife S7 system for stereotaksichesky radio surgery (SRS) and stereotaksichesky radiation therapy (SBRT). The institute of cancer Geyzinger became the first-ever oncological center where the CyberKnife S7 system passed tests and is successfully used for treatment of patients.

According to given the press release, CyberKnife S7 uses AI technologies of tracking and synchronization of the movement in real time and is capable to carry out the SRS and SBRT procedures in only 15 minutes. The company claims that this system of new generation on the CyberKnife platform is capable to treat malignant and benign tumors of the most different localizations and also neurologic frustration.

Accuray submitted the CyberKnife S7 system for stereotaksichesky radio surgery (SRS) and stereotaksichesky radiation therapy (SBRT)

A system adapts the applied radiation depending on needs of the patient. The technology of synchronization of movements Synchrony of the CyberKnife system uses AI for correction of radiation depending on movement of a tumor throughout all course of treatment. Construction of a system allows to change radiator provision. The more potential points of arrangement of the irradiator in space and the more the angles of radiation, the more precisely the doctor will be able to direct a beam to a tumor and the more will reduce defeat of surrounding healthy fabrics.

Developers claim that the CyberKnife system is the only device in the world capable to perform submillimetrichesky stereotaksichesky procedures of any localization without intervention of the person. SRS and SBRT provide the localized radiation therapy which allows to use very high doses of radiation within several days unlike traditional techniques where treatment often requires up to 35 visits. Advantages to patients can include shorter general course of treatment and considerable reduction of risk of ghost effects.^[1]

2018: The first place by efficiency of cancer therapy of a prostate

On September 25, 2018 Accuray published data of two researches of the device for stereotaksichesky radiation therapy of a body of CyberKnife in which its use for treatment of patients with a prostate cancer of low and moderate risk was studied. Data of researches specify that at these patients application of CyberKnife is associated with the maximum survival and the minimum toxicity.

Researches of Accuray company for September, 2018 are the most large-scale assessment of stereotaksichesky radiation therapy of a body at patients with the localized prostate cancer. The vice president for the medical and scientific questions Accuray Fabienne Hirigoyenberry-Lanson notes that a new system allows to achieve the treatment goals, providing at the same time a cost-efficient, noninvasive method which is more convenient for patients, than standard radiation therapy.

System of stereotaksichesky radiation therapy of a body CyberKnife

Data of multicenter researches showed that the survival at patients with low risk when using CyberKnife is 97-100% (at standard radiation therapy of 92-94%), and patients with moderate risk have 88-97% (at standard therapy of 85-90%). The survival of patients of low risk when using CyberKnife was comparable to survival at contact radiation therapy, however was not followed by the risks associated with introduction of a catheter.

At the same time, despite a high dose of radiation, ghost effects of CyberKnife were rather rare, and toxic defeat 3 degrees met at less than 2% of patients above that is comparable using other techniques, however did not require installation of rectal cylinders and laying.

The maximum survival with low toxicity is caused by the directed impact of radiation therapy at which use of a high beam dose with the minimum damage healthy nearby fabrics is possible.^[2]

Notes